Creganna-Tactx Medical, a global Top 10 provider of medical device outsourcing solutions, will showcase the expertise of its CaliforniaCenter of Excellence for Emerging Therapies at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, California.
The largest provider of outsourced product design & development solutions on the West Coast, the company’s California facility is the partner of choice for medical device companies developing breakthrough products for emerging minimally invasive therapies. A single-site solution, the Campbell Center of Excellence provides all of the services and expertise to deliver an approved medical device to market on behalf of its customers.
“Emerging therapies hold enormous commercial potential for our customers” explains David O’Keeffe, Global VP of Sales & Marketing at Creganna-Tactx Medical. “For example, the global Transcatheter Aortic Valve Replacement (TAVR) market is estimated to reach more than $1.5bn by 2015. Over 40 companies are developing novel therapies for the potential $2bn renal denervation market, while next generation technologies such as bioabsorbable stents are forecast to triple yearly growth for the next 5 years.”
“The potential rewards are significant, but developing new categories of devices for emerging therapies is a highly challenging process. Our customers are breaking new ground. Choosing a knowledgeable commercialization partner with specialist insight accelerates that journey to market. Our Campbell team has played a remarkable role in partnering with pioneering companies to get these highly complex products into the hands of physicians faster and more efficiently.”
